Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cipla Vice Chair Explores Lung Leadership Vision With Biosimilars Opportunities

Samina Hamied Also Discusses Industry’s Expectations From Indian Government

Executive Summary

Executive vice chairperson of Cipla Samina Hamied talks to Generics Bulletin about the company’s intention to become global lung leaders on the back of biosimilars opportunities and its inhalation assets. As well as discussing Cipla’s three-year strategy, Hamied – who is also the vice president of IPA – discusses creating a favorable regulatory and policy landscape in India. 

You may also be interested in...



Cipla Founding Family Pares Stake

Founding Hamied family trims holding in Cipla but the third generation currently at the helm operationally underscores that the promoter group remains invested in the front-line firm’s future.

Cipla Founding Family Pares Stake But Third Generation Affirms Continuity

Founding Hamied family trims holding in Cipla but the third generation currently at the helm operationally underscores that the promoter group remains invested in the front-line firm’s future.

Cipla Remains Upbeat On Abraxane As US Generic Competition Looms

Cipla has provided the latest on its US complex pipeline ahead of several potential launches in the firm’s upcoming 2022/23 financial year. The Indian firm enjoyed 6% group revenue growth in Q3 FY2022 and is on track to hit its EBITDA margin target.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel